Active Ingredient History
Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. Tofacitinib was discovered and developed by the National Institutes of Health and Pfizer. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and the treatment of psoriasis and ulcerative colitis. Patients treated with tofacitinib (XELJANZ) are at increased risk for developing serious infections that may lead to hospitalization or death and adverse reactions. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alopecia (Phase 2)
Alopecia Areata (Phase 4)
Aneurysm (Phase 2)
Arthritis (Phase 4)
Arthritis, Juvenile (Phase 3)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Axial Spondyloarthritis (Phase 4)
Cholangiocarcinoma (Phase 1)
Colitis, Ulcerative (Phase 4)
COVID-19 (Phase 2)
Crohn Disease (Phase 2)
Depression (Phase 1/Phase 2)
Dermatitis, Atopic (Phase 2)
Dermatology (Phase 1/Phase 2)
Dermatomyositis (Phase 1)
Diaphragm (Phase 1)
Down Syndrome (Phase 2)
Dry Eye Syndromes (Phase 2)
Eczema (Phase 2)
Glioblastoma (Phase 3)
Glycogen Storage Disease Type II (Phase 3)
Granuloma Annulare (Phase 1)
Granulomatosis with Polyangiitis (Phase 4)
Granulomatous Disease, Chronic (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Hidradenitis Suppurativa (Phase 2)
Ileum (Phase 2)
Immune System Diseases (Phase 2)
Immunomodulation (Phase 1)
Inflammation (Phase 1/Phase 2)
Intestinal Neoplasms (Phase 1/Phase 2)
Keratoconjunctivitis Sicca (Phase 2)
Kidney Failure, Chronic (Phase 1)
Kidney Transplantation (Phase 2)
Leishmaniasis, Cutaneous (Phase 2/Phase 3)
Lung Diseases (Phase 4)
Lung Diseases, Interstitial (Phase 4)
Lupus Erythematosus, Cutaneous (Phase 1/Phase 2)
Lupus Erythematosus, Discoid (Early Phase 1)
Lupus Erythematosus, Systemic (Phase 1/Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Mesothelioma (Phase 1)
Methotrexate (Phase 4)
Myasthenia Gravis (Early Phase 1)
Myositis (Phase 2)
Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 1)
Pharmacokinetics (Phase 2)
Polymyalgia Rheumatica (Phase 3)
Pouchitis (Phase 2)
Psoriasis (Phase 3)
Renal Dialysis (Phase 1)
Rheumatic Fever (Phase 4)
Sacroiliitis (Phase 4)
Sarcoidosis (Phase 1)
Sarcoidosis, Pulmonary (Phase 1)
Scleritis (Phase 2)
Scleroderma, Systemic (Phase 1/Phase 2)
Sjogren's Syndrome (Phase 2)
Spondylarthritis (Phase 4)
Spondylitis (Phase 4)
Spondylitis, Ankylosing (Phase 3)
Stevens-Johnson Syndrome (Early Phase 1)
Substance Withdrawal Syndrome (Phase 3)
Takayasu Arteritis (Phase 4)
Therapeutics (Phase 4)
Thromboembolism (Phase 4)
Uveitis (Phase 2)
Vitiligo (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue